Together, these findings underscore the dual role of MYCN in both driving aggressive tumor growth and modulating immune susceptibility, highlighting the potential use of glycosylation-related gene signatures as valuable predictive tools in neuroblastoma prognosis. The gene discussed is MYCN; the disease is neoplasm.